Pharma Mar SAU (0RC6)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 69.58 |
|---|---|
| 52-week range | 63.60 – 105.40 |
| Return, 1 month / 3 months | −4.9% / −12.0% |
| Return, 1 year / 3 years | −7.9% / +138.5% |
| Trend | Below its 200-day average |
| RSI (14) | 42 |
| Volatility (1 year) | 41.2% |
| Worst drawdown (1 year) | -34.9% |
| Average daily value traded | 0.16M EUR |
| Dividend yield | 1.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Pharma Mar is a Spanish biopharmaceutical company based in Madrid that discovers and develops medicines from compounds found in marine organisms. Its main products are anticancer drugs used in oncology, including treatments derived from sea squirts and other sea life. The company researches and supplies these therapies to hospitals and cancer specialists, and it also works with partners on clinical development. Its work centres on marine natural products as a source of new pharmaceutical treatments.
Pharma Mar SAU trades under the code 0RC6 on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Pharma Mar SAU (0RC6) trades on the London Exchange in UK. It last closed at EUR 69.58 on 23 October 2026.
Its price-based Market X-Ray is 31 out of 100 (a weak price profile), ranking 3,057 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 7.9% and over the last three months it fell 12.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 24 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -14.5% | ||
| From 52-week high | -32.8% | ||
| Momentum | 25 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -12.0% | ||
| 6-month return | -27.6% | ||
| 12-month return, skipping the last month | -3.1% | ||
| Stability (higher is calmer) | 39 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -34.9% | ||
| Liquidity | 35 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.16M EUR | ||
| Zero-volume days | 8.3% | ||
| Income | 32 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.4% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.9% |
|---|---|
| 1 month | −4.9% |
| 3 months | −12.0% |
| 6 months | −27.6% |
| 1 year | −7.9% |
| 3 years | +138.5% |
| 5 years | +3.6% |
Signals
| 50-day / 200-day average | 75.72 / 81.41 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 9.63 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 8 Jul 2026 | EUR 1.0000 |
| 25 Jun 2025 | EUR 0.8000 |
| 12 Jun 2024 | EUR 0.6500 |
| 7 Jun 2023 | EUR 0.5265 |
| 13 Jul 2022 | EUR 0.5265 |
| 28 Apr 2021 | EUR 0.4860 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.